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Abstract Trastuzumab reduces the risk of relapse in
women with HER2-positive non-metastatic breast cancer,
but little information exists on the timing of trastuzumab
initiation. The study investigated the impact of delaying the
initiation of adjuvant trastuzumab therapy for[6 months
after the breast cancer diagnosis on time to relapse, overall
survival (OS), and relapse-free survival (RFS) among
patients with non-metastatic breast cancer. Adult women
with non-metastatic breast cancer who initiated trastuzu-
mab adjuvant therapy without receiving any neoadjuvant
therapy were selected from the US Department of Defense
health claims database from 01/2003 to 12/2012. Two
study cohorts were defined based on the time from breast
cancer diagnosis to trastuzumab initiation:[6 months and
B6 months. The impact of delaying trastuzumab initiation
on time to relapse, OS, and RFS was estimated using Cox
regression models adjusted for potential confounders. Of
2749 women in the study sample, 79.9 % initiated adjuvant
trastuzumab within B6 months of diagnosis and 20.1 %
initiated adjuvant trastuzumab[6 months after diagnosis.
After adjusting for confounders, patients who initiated
trastuzumab[6 months after the breast cancer diagnosis
had a higher risk of relapse, death, or relapse/death than
those who initiated trastuzumab within B6 months of
diagnosis (hazard ratios [95 % CIs]: 1.51 [1.22–1.87], 1.54
[1.12–2.12], and 1.43 [1.16–1.75]; respectively). The
results of this population-based study suggest that delays of
[6 months in the initiation of trastuzumab among HER2-
positive non-metastatic breast cancer patients are associ-
ated with a higher risk of relapse and shorter OS and RFS.
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Introduction
Breast cancer is the most common malignancy in women
and the leading cause of cancer death in women aged
20–59 years [1]. It accounts for 29 % of new cancers in
American women annually, with[200,000 new cases per
year [1]. Today, breast cancer is detected in most patients
in the early stages of disease progression [2–5]. The most
common treatment for such patients includes tumor
removal surgery and adjuvant systemic therapy intended to
kill any cancer cells left behind [6, 7].
In November 2006, the FDA approved trastuzumab as
adjuvant therapy for HER2-positive breast cancer [8, 9], a
subtype of breast cancer that carries an increased risk of
recurrence and overall poor prognosis. The introduction of
trastuzumab has dramatically improved the management of
HER2-positive breast cancer. The efficacy and
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effectiveness of adjuvant trastuzumab in this population
has been confirmed in multiple clinical trials [10–17] and
observational studies [18–26]. Yet, little is known about
the timing of trastuzumab initiation and its impact on
patient outcomes.
Several retrospective studies have evaluated the role of
delayed adjuvant therapy in patients with breast cancer of all
types, reporting mixed results. When treatment delay was
defined as C12 weeks following surgery, a positive rela-
tionship was found between delay and the risk of death [27–
29]. When shorter time intervals were used, most studies
found null associations [30–32], although one study found
that starting adjuvant therapy within 21 days from the sur-
gery date had a beneficial effect [33]. Additionally, a recent
meta-analysis concluded that the risk of death increased by
15 % for each 4-week delay in adjuvant breast cancer
therapy initiation [34]. However, few of these studies have
accounted for the time from diagnosis to surgery, an integral
component of the delay in the initiation of adjuvant therapy.
Furthermore, the studies that did account for the time from
diagnosis to surgery excluded patients with delays in surgery
[27, 28], limiting the generalizability of the results.
Literature is heterogeneous, not only in definitions of
delay in adjuvant therapy, but also in terms of patient,
disease, and treatment characteristics. Since HER2 ampli-
fication is associated with more aggressive tumor biology,
the impact of treatment delay may be different for these
patients. To our best knowledge, only one study [35] has
investigated the optimal time to adjuvant therapy initiation
among patients with HER2-positive breast cancer receiving
trastuzumab, concluding that patients who initiated adju-
vant therapy[60 days after breast cancer surgery had a
threefold increase in the risk of death relative to patients
initiating therapy\30 days after surgery (hazard ratio 3.09,
p = 0.002). However, further studies with contemporary
samples of patients are needed in order to confirm these
findings.
This study aimed to investigate the impact of delaying
the initiation of adjuvant trastuzumab therapy after the
diagnosis of cancer on the risk of relapse, overall survival
(OS), and relapse-free survival (RFS) in a contemporary
sample of patients with HER2-positive non-metastatic
breast cancer who were neoadjuvant naı¨ve prior to surgery.
Methods
Data sources
The US Department of Defense (DOD) Military Health
System (MHS) comprised several databases that include
comprehensive information on the health care and services
provided to[9.5 million active beneficiaries of TRICARE
insurance such as DOD service members, retirees, and their
dependents [36]. The study used the following MHS data
sources: (a) the Defense Enrollment Eligibility Reporting
System (DEERS) database that includes demographic
characteristics of the TRICARE enrollees; (b) the MHS
Data Repository (MDR) claims databases that include both
claims-per-service data for inpatient and outpatient health
services delivered in military or civilian facilities through
the TRICARE healthcare plan, and medication prescrip-
tions for all TRICARE beneficiaries; and (c) the Auto-
mated Central Tumor Registry (ACTUR) that includes
records on the cancer characteristics and cancer recur-
rences of all cancer cases followed by the DOD military
facilities. Data used in this study covered the period from
January 1, 2003 to December 31, 2012. All DOD databases
were linked through identity-masked unique patient iden-
tifiers. Research data were derived from an approved Naval
Medical Center, Portsmouth, VA Institutional Review
Board protocol and comply with the requirements of the
Health Insurance Portability and Accountability Act.
Study design and outcomes
The study included patients with non-metastatic breast
cancer who did not receive neoadjuvant therapy
(chemotherapy, targeted, or hormonal) and were initiated
on adjuvant trastuzumab alone or in combination with
other adjuvant chemotherapy or targeted agents within
1 year of breast cancer surgery (N = 2749, Fig. 1).
The study used a retrospective cohort design (Fig. 2). The
date of the adjuvant trastuzumab initiation, which corre-
sponds to the first trastuzumab infusion received by the
patient after the diagnosis, was defined as the index date.
Two study cohorts were defined based on the time from the
breast cancer diagnosis to the index date: (a) the[6 months
(‘‘delay’’) cohort (n = 552) and (b) the B6 months (‘‘no
delay’’) cohort (n = 2197). The delay in trastuzumab ther-
apy was defined from the breast cancer diagnosis rather than
the breast cancer surgery because delays in surgery are an
inherent part of the delays in the initiation of trastuzumab
therapy, and the aim of the study was to investigate the
impact of delays in trastuzumab therapy initiation, regard-
less of the reasons for the delays. The 6-month cut-off used
to define delay in trastuzumab therapy initiation was selec-
ted based on clinical expertise to allow for sequential ther-
apy with surgery and trastuzumab.
The three outcomes of this study were time to relapse,
OS, and RFS. Relapses were identified in the DOD claims
data using an algorithm based on diagnoses of secondary
malignant neoplasms (using International statistical clas-
sification of diseases, 9th revision, clinical modification
[ICD-9-CM] diagnosis codes), treatment gaps, and treat-
ment initiations, which was developed by the study authors
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by adapting three previously published algorithms [37–39]
to the specifics of adjuvant trastuzumab treatment in non-
metastatic breast cancer [40]. Deaths were identified from
the demographic records in the DEERS database. All three
outcomes were measured and compared between the study
cohorts from the index date to the end of data availability
(December 31, 2012) or the end of continuous healthcare
coverage. Patients’ observation periods were censored if
they reached the end of the database follow-up or of con-
tinuous healthcare coverage without having the event of
interest (relapse and/or death). For the relapse-only out-
come, patients were also censored at the time of death.
Statistical analyses
In unadjusted analyses, the relapse, death, and relapse/
death outcomes were compared between study cohorts
using Chi-square tests, while Kaplan–Meier plots were
used to describe the time to relapse, OS, and RFS (3- and
5-year rates were reported). Outcomes were also compared
between study cohorts using unadjusted Cox regression
models which yielded unadjusted hazard ratios (HRs) and
95 % confidence intervals (CIs).
In adjusted analyses, outcomes were compared between
study cohorts using multivariate Cox regression models
Fig. 1 Sample selection flowchart. aInternational statistical classifi-
cation of diseases, 9th revision, clinical modification [ICD-9-CM]
code 174.x; bFrom January 1, 2003 to December 31, 2012; cTwo
consecutive diagnoses of secondary neoplasms (ICD-9-CM 196.x-
199.x, excluding codes that may be used to indicate locally advanced
breast cancer: 196.0, 196.1, 196.3, and 198.2), within 60 days of each
other; dChemotherapy, targeted or hormonal therapy
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adjusted for the patient’s age at diagnosis, Charlson
comorbidity index (CCI) [41], the type of breast cancer
surgery (breast conserving vs. breast removing), the use of
neoadjuvant and adjuvant radiation therapy prior to the
initiation of trastuzumab, the use of adjuvant hormonal
therapy prior to the initiation of trastuzumab, and the type of
adjuvant therapy regimen (ACTH1-like, TCH2-like, trastu-
zumab monotherapy, trastuzumab ? taxanes, and other
trastuzumab-based regimens). Adjusted HRs and 95 % CIs
were reported. The proportionality of hazards (PH)
assumption was tested by the interaction between the study
cohorts and time and by investigating the crossing of curves
in the Kaplan–Meier plots. Violations of the PH assumption
for all three outcomes indicated that the HR for ‘‘delay’’
versus ‘‘no delay’’ cohort has changed approximately 1 year
after the index date. Therefore, the Cox regression models
were also estimated separately for the period from index
date to 1 year post index date (Period 1) and the period from
1 year post index date to the end of follow-up (Period 2).
Two sensitivity analyses were conducted: one where the
‘‘delay’’ and ‘‘no delay’’ cohorts were defined by the time
from diagnosis to adjuvant therapy initiation (instead of
trastuzumab initiation) using the same cut-off as in the
main analysis (B6 months and[6 months) and the other
one where cohorts were defined by the time from diagnosis
to adjuvant therapy initiation using a 4-month cut-off
(B4 months and[4 months).
Results
Of 2749 women who met the study selection criteria, the
median time from breast cancer diagnosis to trastuzumab
initiation was 3.7 months; 552 (20.1 %) were in the
[6 months (‘‘delay’’) cohort, and 2197 (79.9 %) were in
the B6 months (‘‘no delay’’) cohort (Fig. 1).
Prior to trastuzumab treatment, the study cohorts did not
differ in the type of surgery received (Table 1). However, the
treatments received prior to the index date differed between
the study cohorts: adjuvant hormonal therapy prior to tras-
tuzumab was used by 22.1 % of the patients in the ‘‘delay’’
versus 4.8 % patients in the ‘‘no delay’’ cohort (p\0.001),
and radiation therapy was used by 74.1 % of the patients in
the ‘‘delay’’ versus 52.3 % patients in the ‘‘no delay’’ cohort
(p\0.001, used in adjuvant setting by 97.2 % of the users).
The trastuzumab-based adjuvant therapy regimens also var-
ied between the cohorts, with ACTH-like regimens being the
most common regimens used in the ‘‘delay’’ cohort (41.3 %)
and TCH-like regimens, the most common regimens in the
‘‘no delay’’ cohort (37.2 %, Table 1).
Impact of delays in trastuzumab therapy
on the risk of relapse, OS, and RFS
Over a median follow-up of 3.4 years (inter-quartile range
1.7–5.5 years), 467 relapses and 202 deaths were recorded
among the 2749 patients in the study sample, and the fre-
quency of these events was higher in the ‘‘delay’’ cohort
versus the ‘‘no delay’’ cohort: 24.3 versus 15.2 % patients
experienced a relapse, 11.6 versus 6.3 % patients died, and
26.8 versus 17.6 % patients either had a relapse or died
(p\ 0.001 for all outcomes, Table 2).
Fig. 2 Study design. aTrastuzumab was first approved in 1998 for the
treatment of breast cancer in the metastatic setting, and then approved
in 2006 in the adjuvant setting; the study included 494 patients
without evidence of metastatic disease who received trastuzumab
between 2003 and 2006. bAdjuvant regimen type was identified based
on the chemotherapy and/or targeted therapies received in the period
between the breast cancer surgery and 28 days after the initiation of
trastuzumab. OS overall survival, RFS relapse-free survival
1 ACTH chemotherapy regimen: Anthracycline, a taxane, cyclophos-
phamide, and trastuzumab, with or without other drugs, see Table 1
for details.
2 TCH chemotherapy regimen: taxane, carboplatin, and trastuzumab,
with or without other drugs except anthracycline, see Table 1 for
details.
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Table 1 Comparison of patient characteristics between the study cohorts
[6 months (‘‘delay’’)
cohort
B6 months (‘‘no delay’’)
cohort
p valuea
N = 552 N = 2197
Demographics
Age at the breast cancer diagnosis (years; mean ± SD [median]) 61.3 ± 12.7 [62] 62.8 ± 12.4 [64] 0.010
65? years old, N (%) 236 (42.8) 1079 (49.1) 0.009
Geographic region, N (%)
Southeast 122 (22.1) 564 (25.7) 0.083
West 141 (25.5) 529 (24.1) 0.473
Central 105 (19.0) 489 (22.3) 0.099
Northeast 115 (20.8) 417 (19.0) 0.325
Other 10 (1.8) 62 (2.8) 0.184
Unknown 59 (10.7) 136 (6.2) \0.001
Comorbiditiesb
Charlson comorbidity indexc (mean ± SD [median]) 4.3 ± 2.3 [3] 4.2 ± 2.3 [3] 0.532
Physical comorbiditiesd, N (%)
Hypertension, uncomplicated 278 (50.4) 1209 (55.0) 0.049
Deficiency anemias 199 (36.1) 460 (20.9) \0.001
Valvular disease 107 (19.4) 438 (19.9) 0.771
Diabetes without chronic complications 104 (18.8) 416 (18.9) 0.960
Fluid and electrolyte disorders 103 (18.7) 244 (11.1) \0.001
Hypothyroidism 88 (15.9) 386 (17.6) 0.366
Chronic pulmonary disease 76 (13.8) 414 (18.8) 0.005
Obesity 72 (13.0) 248 (11.3) 0.250
Coagulation deficiency 31 (5.6) 61 (2.8) 0.001
Mental comorbiditiese, N (%)
Depressive disorders 90 (16.3) 356 (16.2) 0.954
Anxiety disorders 70 (12.7) 312 (14.2) 0.356
Sleep-wake disorders 68 (12.3) 277 (12.6) 0.854
Substance-related and addictive disorders 59 (10.7) 258 (11.7) 0.488
Treatment
Adjuvant therapy regimensf, N (%)
ACTH-like 228 (41.3) 534 (24.3) \0.001
TCH-like 53 (9.6) 817 (37.2) \0.001
Trastuzumab monotherapy 100 (18.1) 209 (9.5) \0.001
Trastuzumab ? taxane 36 (6.5) 364 (16.6) \0.001
Other trastuzumab-based regimens 135 (24.5) 273 (12.4) \0.001
Breast-removing surgery prior to initiation of trastuzumab, N (%) 289 (52.4) 1137 (51.8) 0.800
Adjuvant hormonal therapy prior to the index dateg, N (%) 122 (22.1) 106 (4.8) \0.001
Radiation therapy prior to the index dateh, N (%)
Neoadjuvant setting only 3 (0.5) 14 (0.6) \0.001
Adjuvant setting only 391 (70.8) 1123 (51.1)
In both neoadjuvant and adjuvant setting 15 (2.7) 12 (0.6)
Not used 143 (25.9) 1048 (47.7)
Time from breast cancer diagnosis to index date (months, mean ± SD
[median])
8.4 ± 1.9 [8.0] 3.2 ± 1.3 [3.0] \0.001
Time from diagnosis to surgery 1.8 ± 2.5 [0.7] 0.7 ± 0.6 [0.6] \0.001
Time between surgery and initiation of adjuvant chemotherapy 3.3 ± 2.8 [2.2] 0.8 ± 0.9 [1.5] \0.001
Time between initiation of chemotherapy and initiation of trastuzumab 3.3 ± 3.0 [3.1] 0.7 ± 4.8 [0.0] \0.001
Patients with records in ACTURi, N (%) 153 (27.7) 380 (17.3) \0.001
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The RFS Kaplan–Meier curves presented in Fig. 3
suggest the RFS rates were similar between the study
cohorts in the first year after trastuzumab initiation, but the
RFS of patients in the ‘‘delay’’ cohort became lower than
that of the patients in the ‘‘no delay’’ cohort afterward (log-
rank p = 0.007 across the full follow-up). At 3 years after
trastuzumab initiation, the unadjusted RFS rates and 95 %
CIs were 75.0 % (70.9–78.6) in the ‘‘delay’’ cohort versus
81.2 % (79.2–82.9) in the ‘‘no delay’’ cohort. At 5 years,
the corresponding RFS rates and 95 % CIs were 69.8 %
(65.4–73.8) and 76.4 % (74.0–78.5, Fig. 3).
In the overall unadjusted analyses, the risks of relapse,
death, or relapse/death were significantly higher for
patients in the ‘‘delay’’ versus ‘‘no delay’’ cohort
Table 1 continued
N = 153 N = 380
Cancer characteristics in the subset of patients with records in ACTURi
Breast cancer stagej, N (%)
Stage 0 1 (0.6) 0 (0.0) –
Stage I 61 (39.9) 185 (48.7) 0.065
Stage II 68 (44.4) 158 (41.6) 0.545
Stage III 17 (11.1) 35 (9.2) 0.503
Stage IV 0 (0.0) 1 (0.3) –
Missing 6 (3.9) 1 (0.3) 0.003
Tumor histologic grade, N (%)
Grade 1 6 (3.9) 23 (6.1) 0.326
Grade 2 46 (30.1) 124 (32.6) 0.565
Grade 3 84 (54.9) 200 (52.6) 0.635
Grade 4 1 (0.7) 3 (0.8) 0.869
Missing 16 (10.5) 30 (7.9) 0.341
Lymph node status, N (%)
No regional lymph node involvement or isolated tumor cells 76 (49.7) 212 (55.8) 0.200
Some lymph node involvement 68 (44.4) 154 (40.5) 0.406
No regional lymph node involvement, but isolated tumor cells 2 (1.3) 8 (2.1) 0.539
Missing 7 (4.6) 6 (1.6) 0.042
Tumor size (mm, mean ± SD [median]) 22.8 ± 13.6 [20] 26.3 ± 34.4 [20] 0.810
* Statistically significant at p\ 0.05
a Categorical variables were compared between the study cohorts using Chi-square tests; continuous variables were compared between the study
cohorts using Wilcoxon tests
b Comorbidities were measured based on diagnoses recorded in claims during the year prior to the index date
c Charlson comorbidity index (CCI) reflects the presence and extent of several comorbidities that are known to be associated with increased risk
of mortality [41]
d Elixhauser et al. [42]; only comorbidities with frequency[10 % or with statistically significant differences between cohorts (p\ 0.05) are
presented
e DSM-V [43]; only comorbidities with frequency[10 % or with statistically significant differences between cohorts (p\ 0.05) are presented
f Adjuvant treatment regimens were defined based on the chemotherapy and targeted therapy agents received between the surgery and up to
28 days after the first adjuvant trastuzumab; adjuvant treatment regimens were grouped in five mutually exclusive groups, as follows: (a) ACTH-
like regimens included an anthracycline, a taxane, cyclophosphamide, and trastuzumab, with or without other drugs; (b) TCH-like regimens
included a taxane, carboplatin, and trastuzumab, with or without other drugs except anthracycline; (c) trastuzumab monotherapy included only
trastuzumab; (d) trastuzumab ? taxane included trastuzumab and a taxane without the agents required to be defined as ACTH or TCH-like
regiments; and (e) other trastuzumab-based regimens included all regimens not covered by the four categories listed above
g Hormonal therapy between surgery and first trastuzumab by design, no patients received neoadjuvant hormonal therapy
h Radiation therapy between the breast cancer diagnosis and first trastuzumab
i Automated Central Tumor Registry (ACTUR) which includes records on the cancer characteristics and cancer recurrences of all cancer cases
followed by the US Department of Defense (DOD) military facilities
j The charts of 120 patients with missing cancer stage in the ACTUR registry were pulled from the DOD military facilities that followed the
patients and were individually reviewed by EB to assign a stage; for 3 patients in this group, the pathological report was not available in the
patient chart, so the stage was determined clinically; for 7 patients, there was not enough information in the patient chart, so the cancer stage
remains missing (for patients who receive care in both military and civilian facilities, only the patient charts from the military facilities were
available for review)
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Table 2 Impact of delays in adjuvant trastuzumab therapy on risk of relapse, OS, and RFS










Delay versus no delay
Relapse
Main analysis [6 months from diagnosis to trastuzumab
initiation
Overall 552 2197 24.3 15.2 1.51 (1.22–1.87)*
Period 1b 552 2197 6.3 6.3 1.05 (0.71–1.56)
Period 2b 517 2059 19.2 9.5 1.82 (1.40–2.36)*
Sensitivity 1 [6 months from diagnosis to adjuvant
therapy initiation
Overall 213 2536 28.6 16.0 1.92 (1.42–2.60)*
Period 1b 213 2536 7.5 6.2 1.33 (0.77–2.31)
Period 2b 197 2379 22.8 10.5 2.34 (1.63–3.37)*
Sensitivity 2 [4 months from diagnosis to adjuvant
therapy initiation
Overall 494 2255 21.0 16.1 1.31 (1.03–1.67)*
Period 1b 494 2255 5.5 6.5 0.85 (0.55–1.32)
Period 2b 467 2109 16.5 10.3 1.67 (1.25–2.25)*
Death (OS)
Main analysis [6 months from diagnosis to trastuzumab
initiation
Overall 552 2197 11.6 6.3 1.54 (1.12- 2.12)*
Period 1b 552 2197 1.1 1.4 0.88 (0.34–2.27)
Period 2b 546 2166 10.6 4.9 1.67 (1.18–2.35)*
Sensitivity 1 [6 months from diagnosis to adjuvant
therapy initiation
Overall 213 2536 13.1 6.7 1.86 (1.19–2.89)*
Period 1b 213 2536 1.4 1.3 1.05 (0.31–3.59)
Period 2b 210 2502 11.9 5.6 2.07 (1.28–3.33)*
Sensitivity 2 [4 months from diagnosis to adjuvant
therapy initiation
Overall 494 2255 8.3 7.1 1.07 (0.73–1.56)
Period 1b 494 2255 0.8 1.5 0.54 (0.18–1.59)
Period 2b 490 2222 7.6 5.8 1.24 (0.82–1.87)
Relapse or death (RFS)
Main analysis [6 months from diagnosis to trastuzumab
initiation
Overall 552 2197 26.8 17.6 1.43 (1.16–1.75)*
Period 1b 552 2197 7.1 7.3 1.04 (0.72–1.51)
Period 2b 513 2037 21.2 11.1 1.68 (1.31–2.15)*
Sensitivity 1 [6 months from diagnosis to adjuvant
therapy initiation
Overall 213 2536 48.9 14.3 1.74 (1.31–2.32)*
Period 1b 213 2536 8.4 7.1 1.26 (0.75–2.11)
Period 2b 195 2355 24.6 12.2 2.09 (1.47–2.95)*
Sensitivity 2 [4 months from diagnosis to adjuvant
therapy initiation
Overall 494 2255 22.3 18.8 1.13 (0.90–1.43)
Period 1b 494 2255 5.9 7.5 0.75 (0.49–1.15)
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(unadjusted HRs, 95 % CIs: 1.37, 1.12–1.67; 1.36,
1.01–1.83; and 1.30, 1.07–1.57; respectively, results not
shown). After adjusting for potential confounding factors,
the risks remained significantly higher for the ‘‘delay’’
versus the ‘‘no delay’’ cohort (adjusted HRs, 95 % CIs:
1.51, 1.22–1.87; 1.54, 1.12–2.12; and 1.43, 1.16–1.75;
respectively, Table 2). The results of the full Cox regres-
sion models from the overall adjusted main analyses are
presented in eTable 1.
Adjusted analyses were also replicated in Periods 1 and
2 to account for violations of the PH assumption. In Period
1, there were no statistically significant differences
between the study cohorts for all three outcomes (Table 2).
However, in Period 2, the adjusted analyses found
increased risks of relapse, death, or relapse/death for
patients in the ‘‘delay’’ versus ‘‘no delay’’ cohort (adjusted
HR 1.82, 95 % CI 1.40–2.36; adjusted HR 1.67, 95 % CI
1.18–2.35; and adjusted HR 1.68, 95 % CI 1.31–2.15;
respectively, Table 2).
The effect of delay was also stronger in sensitivity
analyses where treatment delay was defined as[6 months
from diagnosis to adjuvant therapy initiation. However, in
sensitivity analyses where delay in initiation of adjuvant
trastuzumab was defined as[4 months from diagnosis to
adjuvant therapy initiation, the effect was weaker, regard-
less of the model used (Table 2).
Discussion
In this community sample of TRICARE beneficiaries, one
in five women diagnosed with HER2-positive non-meta-
static breast cancer initiated adjuvant trastuzumab
[6 months after breast cancer diagnosis. Patients who
experienced a delay in therapy initiation of [6 months
after diagnosis had a higher risk of relapse, death, or
relapse/death than patients who initiated trastuzumab
B6 months after diagnosis; this higher risk became
Table 2 continued










Delay versus no delay
Period 2b 465 2085 17.4 12.2 1.43 (1.08–1.89)*
HR hazard ratio, CI confidence interval
* Statistically significant at p\ 0.05
a Hazard ratios for delay versus no delay in trastuzumab therapy (using several alternative definitions) were adjusted for age, CCI, type of breast
cancer surgery, radiation therapy, adjuvant hormonal therapy, and type of adjuvant therapy regimen
b Due to violations of proportionality of hazards assumption indicating the hazard ratio for delay versus no delay cohort has changed
approximately 1 year after the index date for all three outcomes, the Cox regression models were run separately for the period from index date to
1 year post index date (Period 1) and the period from 1 year post index date to end of follow-up (Period 2). Thus, for Period 1 analyses, patients
follow-up was censored 1 year post diagnosis, while for Period 2 analyses, only patients who were still at risk 1 year post index were included in
the analyses
Fig. 3 Comparison of unadjusted RFS between study cohorts. RFS relapse-free survival
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apparent 1 year after initiation of the trastuzumab
treatment.
Since most previous studies did not provide information
on the HER2 status of patients and used different defini-
tions of delays in treatment, direct comparison of results is
difficult. The only study investigating the impact of therapy
delay among trastuzumab-treated patients with HER2-
positive breast cancer found a higher risk of death among
patients initiating adjuvant therapy[60 days after breast
surgery compared with those initiating therapy within
30 days of surgery [35]. These results support the current
study’s finding of an increased mortality risk associated
with delays in the initiation of adjuvant therapy after breast
cancer diagnosis. A few other studies that stratified the
analyses by hormone receptor (ER) status, another factor
associated with worse prognosis [28, 33], had mixed
results. Lohrisch et al. [28] found that delays of
[12–24 weeks (vs. B12 weeks) in chemotherapy initiation
after surgery were associated with significantly worse OS
only in ER-positive patients. However, Colleoni et al. [33]
found that chemotherapy initiation in node-positive
patients within 21–86 days (vs.\21 days) of surgery had a
detrimental effect on OS in ER-negative but not in ER-
positive patients. Nevertheless, the current study adds to
the results of prior studies [33, 35], suggesting that patients
with more aggressive breast cancer subtypes may benefit
most from early therapy. However, further analyses strat-
ifying patients by prognostic factors at diagnosis would be
necessary to confirm this hypothesis.
Previous studies also used different cut-offs to define
delays in treatment, such as [21 days [30], 21–86 days
[33], 36–89 days [31],[9 weeks [32], 12–24 weeks [28],
and[3 months [27, 29] after surgery. In general, studies
with short cut-offs did not find an association between
delays in adjuvant therapy and OS and/or RFS [30–32],
while treatment delay was associated with a significant
increase in the risk of death and/or relapse in studies with
longer cut-offs [27–29]. Nevertheless, even short delays
post-surgery (of 21–86 days among ER-negative patients
[33] or of[60 days among HER2-positive patients [35])
were associated with an increase in the risk of death/re-
lapse. Overall, these results suggest that the longer the
delay in the initiation of adjuvant therapy and the more
aggressive the tumor type, the stronger the impact of the
delay in treatment on relapse, OS, and RFS outcomes. In
the first sensitivity analysis, where delay was defined based
on the time to adjuvant therapy initiation rather than time
to trastuzumab initiation, the effect was generally stronger,
suggesting that a delay in adjuvant therapy initiation of
[6 months had a substantial impact on the risk of relapse
and death. Conversely, in the sensitivity analysis where
cohorts were defined based on a delay of 4 months between
diagnosis and adjuvant therapy initiation, the overall
impact was weaker, and the impact on the risk of death lost
statistical significance.
Importantly, most studies to date defined adjuvant
therapy delay using the date of surgery, whereas the current
study’s definition uses the breast cancer diagnosis date.
Study designs that define therapy delay as starting with the
date of surgery ignore the inevitable association between
delays in surgery and delays in the initiation of adjuvant
therapy among patients who do not receive neoadjuvant
therapy (i.e., patients in whom delays in surgery are not
justified by the need to downsize a large tumor). If delays
in surgery are correlated with delays in adjuvant therapy or
reduce the benefits of adjuvant therapy, ignoring the delay
in surgery could bias estimates of mortality risks. To
address this limitation, two prior studies [27, 28] excluded
patients with long intervals between the diagnosis and the
surgery ([6 months [27] and [17 weeks [28]). This
approach, however, limited the results’ generalizability.
In the current study, the time to adjuvant trastuzumab
therapy was defined as a combination of three intervals: the
time between (1) diagnosis and surgery, (2) surgery and
adjuvant therapy initiation, and (3) adjuvant therapy initi-
ation and the first trastuzumab treatment (applicable to
ACTH and other chemotherapy regimens with delayed
trastuzumab initiation). The study did not attempt to
identify the individual effect of each interval on patients’
outcomes. While this approach has limitations, the result is
more generalizable for clinical practice: regardless of the
timing of the surgery, initiation of adjuvant therapy
[6 months following the breast cancer diagnosis might
worsen OS and RFS in patients with HER2-positive
tumors. Exploratory analyses among the 552 patients in the
‘‘delay’’ cohort suggested that patterns of delay may be
treatment specific: depending on the treatment regimen, the
interval accounting for most of the delay was either the
time from diagnosis to surgery (i.e., TCH-like regimens,
median 4.8 months) or the time from surgery to adjuvant
therapy initiation (i.e., trastuzumab monotherapy, median
7.6 months; trastuzumab ? taxanes, median 4.7 months)
or the time from adjuvant therapy initiation to first trastu-
zumab (i.e., ACTH-like regimens, median 4.6 months).
However, further studies are needed to investigate factors
driving these delays. Clinical factors may include post-
operation complications, plastic surgery procedures, or
adverse effects of therapies initiated prior to trastuzumab;
non-clinical factors, which are more amenable to inter-
ventions, may include wait times for imaging procedures
and appointments with reconstructive plastic surgeons or
fertility specialists, personal preferences for seeking second
opinions, or financial and geographical constraints.
In this study sample, 11.2 % of the patients received
adjuvant trastuzumab monotherapy as their first treatment
after breast cancer surgery. A minority of patients who
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refuse chemotherapy may be directed toward trastuzumab
monotherapy, while others may have comorbidities that
limit their potential use of chemotherapies. However, it is
unlikely that these factors alone explain the use of trastu-
zumab monotherapy in the study sample. Further studies
are needed to understand the selection of trastuzumab
monotherapy treatment in certain patients. Another finding
was that 51.9 % of the patients in the study sample had
mastectomies, that is more than the \50 % benchmark
proposed by the America College of Surgeons/National
Accreditation Program for Breast Centers [44]. However,
[50 % of the patients in the study had stage II or III
disease, a slightly higher percentage than the general
population initially diagnosed with breast cancer [45]. In
addition, these patients did not receive neoadjuvant
chemotherapy to reduce the size of the primary tumor,
which may have made successful breast conservation sur-
gery more difficult.
This study was subject to the general limitations of
claims data, such as occasional coding inaccuracies. These
likely affect both study cohorts to a similar extent and may
result in a dilution of the observed effect for the delay of
trastuzumab treatment. Additionally, since this is a claims-
based observational study, some potential confounders may
not have been measured and adjusted for in the analyses.
Other study limitations include the identification of relap-
ses through a claims-based algorithm that relies on diag-
noses of secondary neoplasms, treatment interruption, and
treatment re-initiations. While this algorithm was shown to
have 90 % sensitivity and 90 % specificity when validated
against the recurrence records from the ACTUR [40], some
misclassification of relapse events could have occurred.
Second, adjuvant therapy regimens were identified from
claims based on the chemotherapy and targeted agents used
from breast cancer surgery up to 28 days after trastuzumab
initiation, and therefore, some misclassification of the
adjuvant therapy regimens is possible. Third, patients
treated with neoadjuvant therapy were excluded because
delays in surgery/initiation of adjuvant trastuzumab ther-
apy may be justified when treating locally advanced dis-
ease or large tumors. However, only\15 % of the sample
was excluded based on this criterion. Finally, a 6-month
cut-off was used to define ‘‘delays’’ in trastuzumab therapy
initiation. The optimal time of treatment initiation may
vary based on patient characteristics, some of which are
unobservable, and a single cut-off at 6 months post diag-
nosis may result in some misclassification of the patients in
the ‘‘delay’’ versus ‘‘no delay’’ cohorts. However, the effect
of delay weakened in the sensitivity analyses with a shorter
cut-off (4 months), suggesting a longer cut-off is more
likely to capture the impact of treatment delays on relapse
and/or death outcomes.
Conclusion
In a contemporary sample of patients with non-metastatic
breast cancer covered by US Department of Defense insur-
ance, the study found that one in five patients had delays of
[6 months in the initiation of adjuvant trastuzumab therapy
and that these delays were associated with higher risks of
death and relapse. Together with findings from prior studies,
these results suggest that delays in the initiation of adjuvant
treatment may be particularly harmful in patients with more
aggressive tumor types. Furthermore, the study findings also
suggest that the risk was higher when the delay was defined
using a longer cut-off (i.e., 6 months post diagnosis instead
of 4 months post diagnosis). Further studies are warranted to
explore the optimal time of treatment for specific subtypes
of breast cancer and to identify the factors driving delays in
adjuvant trastuzumab therapy initiation.
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